Document is current

Article History

Received: 19 December 2024

Accepted: 12 June 2025

First Online: 30 July 2025

Declarations

:

: During the course of our study, we introduced an additional questionnaire to gather further insights related to “technology readiness”. The questionnaire was provided only to participants who were already active in the CHARIOT PRO Substudy. Informed consent was obtained from all participants within the CHARIOT PRO Substudy. Participation in the questionnaire was entirely voluntary, and respondents were informed that their involvement would not affect their continued participation in the CHARIOT PRO Substudy. All responses were collected and handled in accordance with the confidentiality and ethical standards established for the CHARIOT PRO Substudy.To ensure the quality and integrity of research, the CHARIOT PRO Substudy is conducted in accordance with GCP Guidelines, GPPs issued by ISPE, applicable national guidelines, and to the Declaration of Helsinki 2013, as modified by the 52nd World Medical Assembly (WMA), Edinburgh, Scotland, 2000, and clarified by the WMA General Assembly, Washington 2002 and Tokyo 2004. The study has received approval from the National Research Ethics Service (NRES) Committee London Central (reference 15/LO/0711 [IRAS 140764]), as well as independent ethics review by committees from the local sites.

: Not applicable.

: L.M. reports grants from Johnson and Johnson, Merck, Takeda, Gates Ventures, Eisai, NIHR, UKRI, and research funding from the Davos Alzheimer’s Collaborative (DAC), outside the submitted work, all to Imperial College London. C.U. declares the following funding received through grants or awards, with payments made to their institution: MRC UKRI Applied Global Health Award (2024), National Institutes of Health (2024), Wellcome Leap Dynamic Resilience Grant (2023), Alzheimer’s Association Sex and Gender Differences Award (2023), Davos Alzheimer’s Collaborative Global Cohort Fund (2023), Global Brain Health Institute Project Award (2023), and UK Defence and Security Accelerator Veterans’ Health Innovation Fund (2022). All other authors have no competing interests to disclose.